Year: 2021

Bestyrelsens forslag til de forventede udbytter for 2021 fremgår af nedenstående skema. Det forventede udbytte er vist som kr. pr. andel á 100 kr.Afdeling ISIN-kode Forventet udbytte (kr. pr. andel)European High Yield DK0016205255 2,40US High Yield DK0060477859 0,00Emerging Markets Aktier DK0060184083 8,30Emerging Markets Debt DK0060260602 0,00Bestyrelsen har besluttet, at udbyttet for 2021 vil være minimumsudlodningen, og denne forventes udbetalt den 14. februar 2022. Sidste dag for handel med afdelingen inklusive ret til á conto udbytte: 9. februar 2022 Første dag for handel med afdelingen eksklusive ret til á conto udbytte: 10. februar 2021 Forventet dag for hvornår udbyttet vil være til rådighed på depotkonto: 14. februar 2021 Det endelige udbytte (minimumsudlodningen) forventes offentliggjort umiddelbart efter...

HAMILTON, Ontario, Dec. 02, 2021 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global medtech company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that it has signed contracts with five new US clients, including three physician practices, a home health agency and a hospice provider. “We are pleased to be adding three primary care practices, a home health agency and a hospice care provider as new clients,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “As the Omicron variant raises new concerns about COVID transmission this winter, clinicians are even more motivated to keep their high-risk patients healthy and at home. Reliq’s iUGO Care platform helps protect...

Hofseth Biocare ASA is Now Part of an Exclusive Short-List of Companies to Have Successfully Obtained NDI Status for CalGo® and OmeGo® Nutritional Supplements Extracted from Norwegian Atlantic salmon. Vancouver, British Columbia, 2nd December, 2021 / Globe Newswire / – KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization, KGK Science Inc. (“KGK” or the “CRO”), has successfully assisted its client, Hofseth Biocare ASA (HBC.OL) (“HBC” or the “Client”), to receive New Dietary Ingredient (“NDI”) status from the United States Food and Drug Administration (the “FDA”) for its patented CalGo® and OmeGo® branded...

The INVL Baltic Forests Fund I managed by INVL Asset Management, one of the leading asset management companies in Lithuania, sold its portfolio, which consisted of 1,300 hectares of forests in Lithuania, for EUR 7.5 million, and locked in a 27% average annual rate of return (IRR) for investors. Šiluona UAB, the company that owned the fund’s entire forest portfolio, was acquired by Latvian Forest Company AB. Launched in 2017, the INVL Baltic Forests Fund I invested in forests suitable for forestry activities in the Baltics, mainly Lithuania, and focused heavily on developing a sustainable Lithuanian forest market. It strove to create a consolidated group of forest parcels, thus increasing their value and the potential income. “It was the INVL group’s first fund to apply sustainable forestry management principles. We successfully realized...

Wendel’s 20th annual Investor DayToday, Wendel is hosting its 20th annual Investor Day which is primarily dedicated to showcasing the Group’s unlisted companies. The Executive Board will also present an update on the execution of its 2021-24 roadmap. The Investor Day is an opportunity for the financial community to interact with senior management of the Group’s portfolio companies and to get a detailed view on their long-term value creation. Against a still-uncertain background with the ongoing Covid-19 pandemic, Wendel is determined and has financial resources to deploy capital. Wendel’s investment team which has been further strengthened has a wide range of expertise and its listed and unlisted portfolio companies are in excellent condition. This puts the Group in a favorable position to carry out the roadmap. André François-Poncet,...

Incap Corporation: Incap’s schedule for financial reporting in the year 2022 Incap Corporation will publish the following financial reports in 2022: financial statements release for 2021 on Thursday, 24 February 2022  annual report for 2021 during week 13/2022 (week commencing on 28 March 2022)  business review for January-March 2022 on Wednesday, 27 April 2022  half-year report for January-June 2022 on Thursday, 28 July 2022  business review for January-September 2022 on Thursday, 27 October 2022.The annual report includes the report of the Board of the Directors, the financial statements of the Group and the parent company as well as the auditor’s report for the financial period 1 January–31 December 2021. At the same time, the company will also publish the corporate responsibility report, the report on Corporate Governance as well...

 – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to be confirmed by further in vitro pseudo-virus testing – LONDON and SAN FRANCISCO, Dec. 02, 2021 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced an update to bioRxiv, a preprint server, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations1 of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab. These data were generated through pseudo-virus testing of specific individual mutations found in Omicron. To date, sotrovimab has demonstrated ongoing...